Evidence map›Paper›PMID 27728965›Full record

ArticleGut and liver2017

Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study.

Su Rin Shin, Young Seok Kim, Young-Seok Lim, June Sung Lee, Jin Woo Lee, Sun Myung Kim, Sook-Hyang Jeong, Joo Hyun Sohn, Myung Seok Lee, Sang Hoon Park

Open access · diamondAbstract readEvaluation StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut and liver, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 1 country.

Su Rin ShinHealth Care Center, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
Young Seok KimDepartment of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.
Young-Seok LimDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
June Sung LeeDepartment of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
Jin Woo LeeDepartment of Internal Medicine, Inha University School of Medicine, Incheon, Korea.
Sun Myung KimDepartment of Internal Medicine, Gimpo Woori Hospital, Gimpo, Korea.
Sook-Hyang JeongDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Joo Hyun SohnDepartment of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
Myung Seok LeeDepartment of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea.
Sang Hoon ParkDepartment of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea.
Hallym University Kangnam Sacred Heart Hospital · KRInha University · KRAsan Medical Center · KRHanyang University Guri Hospital · KRKangwon National University · KRKimpo University · KRSeoul National University Bundang Hospital · KRSoonchunhyang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsBecause of the limited geographic distribution, there have been insufficient data regarding hepatitis C virus (HCV) genotype 6 in Korea. This study aimed to investigate the clinical characteristics and available treatment outcomes of patients with genotype 6 HCV in Korea.

methodsFrom 2004 to 2014, data were collected from Korean patients infected with genotype 6 HCV in eight hospitals.

resultsThirty-two patients had genotype 6 HCV. The median age was 44 years, and 6c was the most common subtype. The baseline median alanine transaminase level was 88 (21 to 1,019) IU/mL, and the HCV RNA level was 1,405,000 (96,500 to 28,844,529) IU/mL. Twenty-five patients were treated with peginterferon (PEG-IFN) and ribavirin. Three follow-up losses occurred. Additionally, 13 patients attained a sustained virologic response (SVR), seven patients relapsed, and two patients exhibited a null response. The SVR rates were 40% and 75% for the 24- and more than 48-week treatments, respectively, and five of the six patients who achieved a rapid virologic response (RVR) attained a SVR.

conclusionsKorean patients infected with genotype 6 HCV are relatively young, and 6c is the most common subtype. When treated with PEG-IFN and ribavirin, the SVR rate was 52%. Similar to other genotypes, a longer duration of treatment and attainment of RVR are important for SVR.

Indexed as

AdultAntiviral AgentsDrug Therapy, CombinationFemaleGenotypeHepacivirusHepatitis CHumansInterferon-alphaMaleMiddle AgedPolyethylene GlycolsRepublic of KoreaRetrospective StudiesRibavirinSustained Virologic ResponseAntiviral AgentsInterferon-alphaPolyethylene GlycolsRibavirinGenotype 6Hepatitis C, chronicPeginterferon alfaRibavirin

Identifiers

PMID27728965
PMCPMC5347652
OpenAlexW2531168773

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.